ACCC announces six winners of 2015 Innovator Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE ASSOCIATION OF COMMUNITY CANCER CENTERS announced the six winners of its 2015 Innovator Awards.

This year’s winners are:

  • Eastern Maine Medical Center Cancer Program, for improving efficiency, safety and the patient experience with location technology.
  • Lancaster General Hospital and the Ann B. Barshinger Cancer Institute, for creating a Cancer Patient Support Fund for patients experiencing financial distress.
  • Mary Washington Healthcare Regional Cancer Center, for the center’s focused “prehabilitation” program that couples physical therapy with holistic care that includes nutritional support, stress reduction strategies and nurse navigator intervention, which decreased hospital length of stay for thoracic oncology patients by 40 percent.
  • PIH Health Comprehensive Community Cancer Program, for its nurse practitioner-run Lung Cancer Screening Program that utilizes an enrollment method that allows primary care practitioners to refer patients or for the patient to self-refer.
  • Providence Cancer Center, which offers a supportive group model to deliver early and ongoing intervention and support throughout cancer care and creating a framework to talk about the impact of cancer on the family.
  • The Seton Cancer Program of the Seton Family of Hospitals, for developing a standardized, integrated database of clinical and business metrics to measure, analyze and improve patient care and operational efficiency.

More details about each program are available on the ACCC website.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login